New hope for cushing syndrome: Long-Term drug safety trial underway
NCT ID NCT03604198
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This study looks at the long-term safety of a drug called relacorilant for people with Cushing syndrome. It includes 125 adults who already completed a prior study and may benefit from continuing treatment. The main goal is to track any side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUSHING SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 1
Indianapolis, Indiana, 46202, United States
-
Site 10
Atlanta, Georgia, 30318, United States
-
Site 11
Dallas, Texas, 75390, United States
-
Site 12
Houston, Texas, 77079, United States
-
Site 13
Fall River, Massachusetts, 02721, United States
-
Site 14
Vienna, 1090, Austria
-
Site 16
Munich, Germany
-
Site 17
Madrid, 28007, Spain
-
Site 18
Girona, Spain
-
Site 19
Seville, Spain
-
Site 2
Pittsburgh, Pennsylvania, 15212, United States
-
Site 20
Ramat Gan, 5265601, Israel
-
Site 21
Naples, 80131, Italy
-
Site 24
New York, New York, 10021, United States
-
Site 25
Milan, 20145, Italy
-
Site 27
Baltimore, Maryland, 21287, United States
-
Site 28
Bucharest, 11863, Romania
-
Site 29
Tel Aviv, 64239, Israel
-
Site 3
St Louis, Missouri, 63110, United States
-
Site 31
Bucharest, 10825, Romania
-
Site 32
Fort Worth, Texas, 76132, United States
-
Site 33
Rotterdam, 3015 GD, Netherlands
-
Site 34
Jackson, Mississippi, 39202, United States
-
Site 35
Stanford, California, 94305, United States
-
Site 36
Rochester, Minnesota, 55905, United States
-
Site 37
Bucharest, 050474, Romania
-
Site 38
Málaga, 29006, Spain
-
Site 39
Torrance, California, 90502, United States
-
Site 4
Wilmington, North Carolina, 28401, United States
-
Site 40
Ancona, 60126, Italy
-
Site 42
Würzburg, 97080, Germany
-
Site 43
Cleveland, Ohio, 44195, United States
-
Site 44
Messina, 98125, Italy
-
Site 45
Lublin, 20412, Poland
-
Site 46
Pittsburgh, Pennsylvania, 15213, United States
-
Site 47
Krakow, 30-688, Poland
-
Site 48
Padova, 35128, Italy
-
Site 49
Phoenix, Arizona, 85013, United States
-
Site 5
Metairie, Louisiana, 70006, United States
-
Site 50
Miami, Florida, 33136, United States
-
Site 51
Nova Scotia, Canada
-
Site 52
Torino, Italy
-
Site 53
Alicante, Spain
-
Site 55
Reno, Nevada, 89511, United States
-
Site 6
Albany, New York, 12206, United States
-
Site 7
El Paso, Texas, 79935, United States
-
Site 8
Ann Arbor, Michigan, 48109, United States
-
Site 9
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.